Novo Nordisk spotlights future innovations within diabetes as insulin sales recede
![Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk | Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13812384.ece/ALTERNATES/schema-16_9/doc7k1vrch540m159585njl.jpg)
A number of bleak years for pharmaceutical firm Novo Nordisk’s insulin business, particularly in the US, have been replaced by a bright outlook.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.